Halozyme Using ENHANZE™ Technology

 

SAN DIEGO, Jan. 21, 2016 — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme’s proprietary ENHANZE™ technology.

“We are pleased that the first product candidate with AbbVie has been advanced into clinical testing just seven months after forming our collaboration agreement,” said Dr. Helen Torley, president and chief executive officer. “The progress is encouraging as we seek to help an even broader population of patients with our ENHANZE platform.”

The initiation of clinical evaluation triggered a $5 million milestone payment to Halozyme under the  Collaboration and License Agreement between the companies.

Subscribe to get the latest news